The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats

Creating and curing fatty hearts

(2010) Raffay S Khan et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts

(2009) Vilma A. Sardão et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974

(2009) Karen Y. Wonders et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase II  in Breast Cancer Cells

(2009) V. A. Rao et al.   CANCER RESEARCH

Intercellular communication of cellular stress monitored by γ-H2AX induction

(2009) Jennifer S. Dickey et al.   CARCINOGENESIS

Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage

(2009) Elif Tatlidede et al.   FREE RADICAL RESEARCH

The iron chelator Dp44mT does not protect myocytes against doxorubicin

(2009) Brian B. Hasinoff et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity

(2008) M MITRA et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY